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ABSTRACT: In silico-based optimization of Ir/P,S-catalysts for the
asymmetric hydrogenation of unfunctionalized olefins using (E)-1-
(but-2-en-2-yl)-4-methoxybenzene as a benchmark olefin has been
carried out. DFT calculations revealed that the thioether group has a
major role in directing the olefin coordination. This, together with the
configuration of the biphenyl phosphite group, has an impact in
maximizing the energy gap between the most stable transition states
leading to opposite enantiomers. As a result, the optimized catalyst
proved to be efficient in the hydrogenation of a range of alkenes with
the same substitution pattern and olefin geometry as the benchmark
olefin, regardless of the presence of functional groups with different coordination abilities (ee values up to 97%). Appealingly, further
modifications at the thioether groups and at the biaryl phosphite moiety allowed the highly enantioselective hydrogenation of olefins
with different substitution patterns (e.g., α,β-unsaturated lactones and lactams, 1,1′-disubstituted enol phosphinates, and cyclic β-
enamides; ee values up to >99%).
■ INTRODUCTION
The preparation of enantiomerically enriched compounds has
become central in the chemical industry in general, and in the
pharmaceutical and phytopharmaceutical industry in particular,
enabling the production of compounds with increased
biological efficacy, less adverse effects, and less costs.1 Metal-
catalyzed asymmetric hydrogenation with hydrogen gas has
postulated itself as a key technology for the preparation of
these types of chiral compounds. Their advantages are high
atom economy, low catalyst loadings, and operational
simplicity.1,2 The extensive research dedicated to the
asymmetric hydrogenation of prochiral olefins has resulted in
catalysts capable of efficiently reducing olefins with very
diverse structures. Despite the advances, each catalyst only
provides optimal results for a restricted range of olefins. For
example, while Ru/Rh-diphosphines are the most suitable for
the hydrogenation of functionalized substrates,3 the catalysts of
choice for the hydrogenation of unfunctionalized olefins are Ir-
P,N catalysts.4 In between the unfunctionalized olefins and the
analogues with coordinating functional groups, there is a wide
range of interesting substrates with intermediate coordinating
properties, such as α,β-unsaturated esters, lactones, lactams,
and ketones, for which Ir-catalysts have been superior to Rh/
Ru-catalysts.4 Nevertheless, the effectiveness of these Ir-
catalysts again depends on the geometry and substitution
pattern of the olefin.4 The identification of a catalyst useful for
substrates with functional groups with varying coordination
abilities and with different substitution patterns remains a
central task in asymmetric hydrogenation.
The bottleneck in finding the optimal catalyst is the
identification of the right family of ligands.5 The discovery of
an efficient ligand is mostly carried out empirically, ranging
from trial-and-error approaches to more or less rational designs
based on mechanistic studies. This process has been aided by a
variety of procedures for evaluation of catalysts, such as high-
throughput experimentation, but still remains costly.5 These
semi-empirical approaches can reject good ligands that
unfortunately deemed not successful during the initial
screening not because the ligand was not good but because
it was not tested under the right conditions. Nowadays, catalyst
discovery is being aided by the advances in DFT computa-
tional simulations but its use is mostly focused on justifying
exciting catalytic results instead of foreseeing potential uses.
Over the past decade, we have demonstrated that Ir-catalysts
modified with chiral P,thioether ligands are good alternatives
to the commonly used Ir-P,N catalysts in the asymmetric
hydrogenation of olefins without coordinative groups owing to
the fact that thioether groups are more stable than oxazolines
and generate an additional stereogenic center near to Ir, which
confers a different steric environment around the metal
center.6 Several families of P,thioether ligands synthesized in
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a few steps from inexpensive sources gave results comparable
to the best reported data. We have also shown that their
optimization could be aided by DFT calculations.6c In this
article, we go one step further and we first make use of DFT
calculations to study in silico the possibilities of new types of
P,thioether ligands. The findings are then validated exper-
imentally in the laboratory. To speed up the simulation
process, the ligand design must limit the number of
conformations energetically available of the chelate ring as
well as restrain the flexibility at both the thioether and
phosphorous moieties. One ligand class especially well suited
in limiting the number of conformations of the chelate ring is
that containing a chiral 1,1′-binapththalene core (such as
BINOL, BINAP...).5(b) Therefore, we started the calculations
with diastereomeric binaphthyl-based phosphite-thioether
ligands L1 and L2, which contain an easy to compute methyl
thioether group and fixed configurations of the biphenyl
phosphite moiety (Figure 1). It is to note that this type of
heterodonor binaphthyl-based P, thioether led to the first
applications of P,S ligands in asymmetric processes, such as
hydroformylation, hydrogenation, and allylic alkylations.7
However, the fact that only promising results were reached
in allylic alkylation limited further developments, in contrast to
the high applicability and success of BINAP-type ligands.
■ RESULTS AND DISCUSSION
Theoretical Ligand Design. We initially focused the
catalyst design on the Ir-catalyzed asymmetric hydrogenation
of unfunctionalized olefins using (E)-1-(but-2-en-2-yl)-4-
methoxybenzene S1 as a benchmark olefin. Their reduction
is less established than the hydrogenation of functionalized
olefins. Most catalysts are still sensitive to the number and
nature of substituents, and important olefins still provide
suboptimal results.4 Mechanistically, the hydrogenation of
these types of substrates proceeds via IrIII/IrV species as
demonstrated both theoretically and experimentally.8 The
enantioselectivity-determining step is the transfer of the first
hydrogen atom to the coordinated alkene. This step, however,
can proceed via two different pathways. Usually, the most
energetically favorable pathway is the one that involves the
migratory insertion of the hydride (Figure 2). However, the
alternative σ-bond metathesis pathway is also energetically
feasible (Figure 2). Thus, we computed all possible transition
states (TSs) for the migratory insertion and σ-bond metathesis
pathways with ligands L1 and L2 using S1 as a benchmark
unfunctionalized olefin.
Due to the lack of symmetry of ligands L1 and L2, we had to
consider the relative position of the axial hydride and the
hydrogen molecule (up or down) as well as the configuration
of the coordinated thioether moiety, the face selectivity of
coordination of the olefin (re and si), and the regioselectivity of
the hydrogen insertion toward the most and least substituted
olefinic carbon atom. In line with previous studies, our
calculations indicated that the migratory insertion is more
favorable than the σ-bond metathesis (see the Supporting
Information). Table 1 shows the two most stable TSs leading
to enantiomers R and S of the hydrogenated product for each
ligand. The simulations also predicted that the catalyst with
ligand L2 should provide higher enantioselectivities than that
with L1.
The theoretical results were then validated by synthesizing
the corresponding catalyst precursors [Ir(cod)L]BArF (L = L1
and L2) and testing them in the hydrogenation of S1 under
standard conditions (Scheme 1).6 As predicted by the
calculations, ligand L2 gave higher enantioselectivity than L1.
In addition, our computational results showed that the most
favored TSs for each ligand have the same chirality at the
coordinated sulfur atom and the same hydride/hydrogen
disposition (Table 1). This finding significantly simplifies the
analysis because the ligand disposition is the same in all cases
and the TSs only differ on the olefin orientation and on the
Figure 1. Binaphthyl-based phosphite-thioether ligands L1 and L2.
Figure 2. Representation of the transition states for the migratory
insertion and σ-bond metathesis hydrogenation pathways (X = N, S,
or O).
Table 1. Summary of the Most Favored TSs for the
Migratory Insertion with Ir/L1 and Ir/L2 Catalysts with
Substrate S1a
aRelative energies in kcal/mol. The sulfur chirality for each TS is
given in parenthesis. The naming of the TSs includes the ligand, the
prochiral face olefin coordination (re or si), and the + symbol to
indicate that the MI takes place at the most substituted carbon or the
− symbol to indicate that the MI occurs at the less substituted carbon.
bEnergies relative to that of TSL1/re‑.
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olefinic carbon in which the migratory insertion takes place.
Taking this into account, we developed a model to rationalize
the origin of the enantioselectivity induced by each ligand. For
that, we used the quantitative quadrant-diagram representation
of the molecular system (MolQuO).9 To begin with, we
studied the system without the olefin to analyze the sterically
hindered and free regions of the catalyst (Figure 3). For both
ligands, the most occupied quadrant is the one with the
thioether substituent.
Then, we evaluated the change in the arrangement of the
ligand around the metal center in the most favored TSs of each
ligand (Figure 4). Note that this analysis was done taking the
geometry of the whole TS, as shown in the figure, but
removing the atoms of the olefin in the MolQuO calculation
(see Computational Details). For both catalysts, the most
occupied quadrant is still the one with the substituent of the
thioether moiety. In addition, the less energetic TSs tend to
have the most hindered quadrant occupied by the olefinic
hydrogen (as one would expect) or the olefinic aryl moiety.
This latter result can be explained by the fact that either the
planarity of the aryl ring reduces the steric clash with the
thioether’s methyl or the existence of a C−H π-stacking
interaction between the substrate’s aryl ring and the methyl of
the thioether substituent. These interactions are clearly seen in
NCI plot analysis (see the Supporting Information for more
details). In this case, the steric constrains seem to be the main
reason in the stabilization of TSs with the aryl olefinic moiety
at the most occupied quadrant because attractive interactions
with the olefinic aryl ring are found in all the possible TSs
owing to the aromatic nature of the ligand.
A further analysis of the calculated structures allows us to
explain the different enantiocontrol exerted by the complexes
with ligands L1 and L2. For that purpose, we should pay
attention to the upper right quadrant. For L1, this quadrant is
hardly occupied by the ligand without the olefin (Figure 3) but
it becomes occupied in the most stable TS (TSL1/re‑; Figure 4).
This is due to the fact that there is an attraction between the
olefinic hydrogen and the ligand, which can be visualized by
the reduction of the P-O-C angle of the binaphthyl moiety
from 125.7° (the angle without the olefin) to 122.3° (Figure
5). Note that one would expect the transition state TSL1/si+ to
be the most favorable due to the presence of the olefinic
hydrogen at the most sterically hindered quadrant (Figure 4).
Although the attraction between the aryl group of the olefin
with the ligand still exists (as seen in an NCI plot analysis, see
the Supporting Information for more details), to minimize the
steric clash, the angle P-O-C in TSL1/si+ increases to 128.8° to
accommodate the aryl group of the olefin and the Ir−P bond
gets longer (Figure 5). This distortion makes the TSL1/si+ less
stable than one would a priori expect. As a result TSL1/si+ and
TSL1/re‑ have similar energies. This explains the low
enantioselectivity obtained when using ligand L1.
In contrast to L1, for L2, the occupation of the upper right
quadrant is similar in the two most stable TSs (TSL2/re+ and
TSL2/si‑, Figure 4) and therefore the interaction between one of
the olefinic methyls and the ligand is similar. As a consequence,
the energy difference between both TSs can be attributed to
the different steric effects when the most hindered quadrant
(the lower left quadrant) is occupied by the olefinic hydrogen
(for the TSL2/re+ leading to the S product) or the olefinic
aromatic group (for the TSL2/si‑ leading to the R product).
Therefore, there is a preferred stabilization of the TSL2/re+ due
to the presence of the olefinic hydrogen at the most sterically
hindered quadrant. This situation increases the energy gap
between the TSL2/re+ and TSL2/si‑ and could explain the higher
enantiomeric excess achieved with Ir/L2 in the S product
compared with Ir/L1.
The above results demonstrate the key role of the thioether
substituent in the enantiodiscrimination and the importance of
the methyl thioether substituent to force the olefinic hydrogen
to preferentially occupy the most hindered quadrant. This
finding suggests that ligand modifications able to block even
further this quadrant would destabilize the TS that places the
olefinic aryl group at the most hindered quadrant and therefore
would lead to higher enantioselectivities. A simple way to
check this was to introduce a bulkier thioether substituent and
check by MolQuO how this affected the quadrants’ diagram.
We considered three thioether substituents L3−L5, and, to
simplify the calculations, we studied the three systems without
the olefin (Figure 6). As it could be expected, the bulkier the
thioether substituent, the more effectively the quadrant is
blocked and therefore it should provide higher ee values.
To verify our hypothesis, we prepared two of the three Ir-
catalyst precursors, containing ligands L3 (R = iPr) and L5 (R
= Cy), and applied them in the asymmetric hydrogenation of
S1 (Table 2). We also included in this study four new Ir-
catalyst precursors with analogue ligands L6−L9, which
contains a flexible biphenyl phosphite moiety (Table 2) in
order to evaluate whether the joint action of the binapththyl
ligand backbone and the thioether substituent is able to control
the tropoisomerization of the flexible biphenyl phosphite
moiety.
In line with the calculated occupancy of the quadrants, the
results indicated that enantioselectivities increase as the alkyl
groups at the thioether get bulkier: Me (ligand L2) < iPr
(ligand L3) < Cy (ligand L5).
Scheme 1. Asymmetric Hydrogenation of S1 Using [Ir(cod)
L]BArF (L = L1 and L2)
a
aComparison with the theoretical results.
Figure 3. Models of Ir-catalysts with ligands (a) L1 and (b) L2
without the olefin. The partial occupation of each quadrant according
to MolQuO is shown. Note that for each ligand, this analysis was
done with the favored hydride/hydrogen disposition.
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The results with ligands L6−L9 indicated that the presence
of an achiral biphenyl phosphite moiety decreases enantiose-
lectivities (e.g., entries 1−3 vs 4, 5, and 7, respectively).
Therefore, the chiral binaphthyl ligand backbone together with
the thioether group is not able to efficiently prevent the
tropoisomerization of the biphenyl phosphite moiety in ligands
L6−L9.
It is to note the very low enantioselectivity of ligand L8 with
a phenyl thioether group (entry 6). This was unexpected
because with the analogous ligand L4 (Figure 6), containing a
chiral biaryl phosphite group, the hindered quadrant is highly
Figure 4. Models of the most favored transition states for Ir-complexes with ligands L1 and L2.
Figure 5. Comparison of calculated structures of TSL1/re‑ and TSL1/si+ with the model structure without the olefin.
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occupied (Figure 6). This can be explained by the ability of the
phenyl thioether substituent to establish a π-stacking
interaction with the olefinic aryl ring that we observed in
DFT calculations of the TSs with the analogous catalyst with
ligand L4. It was seen that there is almost no energy difference
(Δ(ΔG)# = 0.34 kcal/mol) between the two most stable TSs
containing, at the most hindered quadrant, the olefinic
hydrogen (TSL4/re+) or the olefinic aryl substituent (TSL4/si‑;
see the Supporting Information).
Asymmetric Hydrogenation of Other Substrates:
Scope and Limitations. We next studied whether our
computationally based catalyst design can be extended to other
olefins with the same geometry and substitution pattern as S1
(Figure 7).10 The Ir/L5 catalyst was used as it provided the
best results. Interestingly, the design proved to work even
better than that for S1 when replacing the methyl groups by
either a phenyl (olefin S2 and S3) or polar groups with
different coordinating abilities (from olefin S4 with a
coordinative group that is expected not to form a stable
chelate ring with iridium to S5 and S6 with coordinative
groups that can bind to the metal). For all of them, high
enantioselectivities (up to 97% ee) comparable to the best one
reported were attained, demonstrating the usefulness of this
computational approach for designing a catalyst. The effective
reduction of enol phosphinates and alkenylboronic esters is of
particular importance because they can further be transformed
into high-value products such alcohols (an alternative pathway
to the reduction of ketones) and chiral boron compounds
(whose C−B bond can be easily converted to chiral C−C, C−
N, and C−O bonds).11 Despite their importance, they have
been less studied than other trisubstituted olefins with polar
functional groups. In addition, one can highlight the effective
reduction of the purely alkyl-substituted enol phosphinate S6,
a good alternative to the reduction of dialkyl ketones to
alcohols with Rh/Ru-systems whose hydrogenation remains
elusive.
To further establish the application range of Ir/L1−L9, we
moved to the asymmetric hydrogenation of other relevant
olefins with poorly coordinative groups such as α,β-
disubstituted unsaturated ketones, lactones, and lactams
(Figure 8).12 Their reduction is of interest because it facilitates
installing a tertiary chiral stereocenter at the α-position of a
carbonyl, lactone, and lactam group. Such motifs are present in
many natural products, drugs, and commodity chemicals.2b,13
However, they do not resemble S1 or related substrates S2−
S6, neither in the olefin substitution pattern nor in the
polarization of the alkene. As a result, it should be expected
that the computed catalyst design would not completely fit
such substrates, and we therefore screened all the catalyst
precursors prepared (see the Supporting Information for the
full set of results). We identified Ir/L1, with an opposite
configuration of the biaryl phosphite moiety rather than Ir/L5
and with a methyl thioether substituent, as a suitable catalytic
system for their reductions (Figure 8). Ir/L1 provides excellent
enantiocontrol in the hydrogenation of α,β-disubstituted
unsaturated lactones and lactams (S10−S12; ee values up to
>99 and 97%, respectively), comparable to the best reported so
far.
Ir/L1−L9 catalyst precursors were also tested in the
reduction of 1,1′-disubstituted alkenes (S13−S20; Figure 9).
These are less hindered than the previously studied
trisubstituted olefins, and face-selectivity is harder to control.
In addition, they can isomerize to the most stable E-
trisubstituted olefins, which are reduced to the opposite
enantiomers. The effective reduction of these alkenes was only
reached recently and with a limited number of catalysts.14 We
selected a set of 1,1′-disubstituted olefins with different
functional groups that covers from no coordinative (S13−
Table 2. Asymmetric Hydrogenation of S1 Using Ligands
L3 and L5−L9a
aReaction conditions: 0.25 mol S1, 1 mol % [Ir(cod)L]BArF, PH2 =
100 bar, rt., 18 h. bConversion measured by 1H NMR. Isolated yield
in parenthesis. cEnantiomeric excess determined by GC.
Figure 7. Asymmetric hydrogenation of trisubstituted olefins S2−S6.
Reaction conditions: 1 mol % [Ir(cod)L5]BArF, CH2Cl2 as a solvent,
100 bar H2, rt., 18 h. Full conversions were attained in all cases.
Figure 8. Asymmetric hydrogenation of α,β-disubstituted unsaturated
ketones, lactones, and lactams S7−S12. Reaction conditions: 1 mol %
[Ir(cod)L1]BArF, CH2Cl2 as a solvent, 100 bar H2, rt., 18 h. Full
conversions were attained in all cases.
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S18) to coordinative (S19 and S20). Substrates S13−S17
could be effectively hydrogenated with Ir/L2 (ee values up to
94%) independent of the steric and electronic character of the
substituent in the aryl group. Like in most successful reports,
the reduction of S18 with a less sterically alkyl substituents
proceeded with lower enantioselectivities due to the isomer-
ization side reaction.14,15 It is also to note that the high
enantioselectivity reached in the reduction of trisubstituted
enol phosphinates was also retained for the more challenging
1,1′-disubstituted analogue S19 and even in the reduction of
the purely alkyl-substituted S20, but with the Ir/L9 system,
which has an achiral biphenyl phosphite moiety.
Finally, we studied the asymmetric hydrogenation of cyclic
β-enamides (Figure 10). Their hydrogenation opens up a
straightforward route to the synthesis of the 2-amino-1,2-
dihydronaphthalene core, which is present in many natural
products and pharmaceuticals (e.g., rotigotine, alnespirone,
and robalzotan).16 Although cyclic β-enamides have the same
substitution pattern as olefins S7−S12, they contain a strong
coordinating group, which has been the focus of most of the
research in Rh/Ru-catalysts with a limited success and
substrate scope.17 More recently, Riera’s group made an
important breakthrough by using Ir-P,N catalysts, commonly
used for unfunctionalized olefins, that could reduce cyclic β-
enamides derived from 2-tetralones with better results than
those reported with Ru/Rh-catalysts.18 Subsequently, our
group showed that Ir-P,thioether catalysts also have a
comparably high catalytic performance.19 We initially studied
the reduction of N-(3,4-dihydronaphthalen-2-yl)acetamide
S21 as the benchmark alkene under the optimal reaction
conditions previously reported.19 The screening of Ir/L1−L9
catalytic systems allowed us to identify Ir/L2 as an efficient
catalytic system for the hydrogenation of S21 (see the
Supporting Information). The excellent enantiocontrol was
extended to a range of cyclic β-enamides derived from 2-
tetralones, displaying all possible substitution patterns at the
fused benzene ring and with several substituents (S21−S26;
Figure 10). High ee values were also attained in the
hydrogenation of a 3-chromanone derivative (substrate S27)
as well as of the linear β-enamide S28. Among these successful
reductions, note those with substrates S26 and S27, which are
precursors for the drugs rotigotine and alnespirone, respec-
tively.
■ CONCLUSIONS
We have shown the feasibility of in silico optimization of Ir/
P,S-catalysts for the asymmetric hydrogenation of (E)-1-(but-
2-en-2-yl)-4-methoxybenzene S1. The key to speed up the
process has been the election of the highly rigid chiral 1,1′-
binapththalene core, which reduces the number of conforma-
tions of the chelate ring. DFT calculations revealed that the
bulkiness of the thioether has a major role in blocking, with
more or less success, one of the quadrants. As a result, it is
possible to direct the olefin coordination, thus overcoming very
common face selectivity issues and controlling the relative
position of the axial hydride and the hydrogen. Calculations
also showed that the chirality of the biphenyl phosphite needs
to be controlled to maximize the energy gap between the most
stable TSs leading to opposite enantiomers. We therefore
discovered the Ir-L5 catalytic system, which contains a
cyclohexyl thioether group and an S-biphenyl phosphite
group, as the most enantioselective for the hydrogenation of
S1. Appealingly, the high enantiocontrol exerted by the Ir-L5
catalyst was maintained in the hydrogenation of other olefins
containing the same substitution pattern and olefin geometry,
regardless of the presence of other functional groups or their
coordination abilities. Interestingly, further modifications on
the thioether groups and the biaryl phosphite moiety allowed
the highly enantioselective hydrogenation of olefins with
different geometry patterns (such as α,β-unsaturated lactones
and lactams, 1,1′-disubstituted enol phosphinates, and cyclic β-
enamides). To sum up, we here showed the usefulness of an in
silico-based catalyst optimization for the discovery of an
efficient Ir-P,S catalyst family, whose application in asymmetric
catalysis had been discarded because early studies failed.
■ EXPERIMENTAL SECTION
General Considerations. All syntheses were performed by using
standard Schlenk techniques under an argon atmosphere. Solvents
were purified by standard procedures. Phosphorochloridites are easily
prepared in one step from the corresponding biaryls.20 The synthesis
of binol-based hydroxyl-thioether ligand precursors is discussed in the
Supporting Information. All other reagents used were commercially
available. 1H, 13C{1H}, and 31P{1H} NMR spectra experiments were
recorded using a 400 MHz spectrometer. Chemical shifts are relative
to that of SiMe4 (
1H and 13C) as an internal standard or H3PO4 (
31P)
as an external standard. 1H and 13C assignments were done based on
1H-1H gCOSY and 1H-13C gHSQC experiments.
Computational Details. All minima and TSs were located using
the Gaussian 09 program,21 employing the B3LYP22 density
Figure 9. Asymmetric hydrogenation of 1,1′-disubstituted alkenes
S13−S20. Reaction conditions: 1 mol % [Ir(cod)L]BArF (L = L2 for
substrates S13−S18; L = L9 for S19 and S20), CH2Cl2 as a solvent,
100 bar H2, rt., 18 h. Full conversions were attained in all cases.
Figure 10. Asymmetric hydrogenation of β-enamides S21−S28.
Reaction conditions: 1 mol % [Ir(cod)L2]BArF, CH2Cl2 as a solvent,
100 bar H2, rt., 12 h. Full conversions were attained in all cases.
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functional along with Grimme’s dispersion correction GD3.23 The 6-
31G*24 basis set was used for all atoms except for iridium, for which
the LANL2DZ25 basis set was used together with the corresponding
electron core potential. Solvent effects were taken into account along
geometry optimizations using the polarized continuum model PCM26
with default parameters for dichloromethane. Frequency calculations
have been carried out to check the nature of the located species and to
obtain the free energies in solution. The energies were further refined
by performing single point calculations with PBEPBE27 as the density
functional along with Grimme’s dispersion correction GD228 and the
6-311G*29 basis set for all elements except iridium. This is owing to
the high accuracy of this calculation method observed by Hopmann in
the iridium mediated hydrogenation reactions.30 All energies reported
are Gibbs free energies in solution with the Quasi-Harmonic
approximation31,32 at 298.15 K and in kcal mol−1 (see the Supporting
Information for further details).
General Procedure for the Preparation of Phosphite-
Thioether Ligands. Ligands L1−L9 were prepared following a
methodology previously developed in our group.6d The correspond-
ing phosphorochloridite (1.1 mmol) produced in situ was dissolved in
toluene (5 mL), and triethylamine (2.2 mmol, 0.3 mL) was added.
The corresponding hydroxyl-thioether compound (1 mmol) was
azeotropically dried with toluene (3 × 1 mL) and dissolved in toluene
(5 mL) to which triethylamine (2.2 mmol, 0.3 mL) was added. The
solution was transferred slowly at 0 °C to the solution of the
phosphorochloridite. The reaction mixture was stirred overnight at 80
°C, and the triethylamine salts were removed by filtration.
Evaporation of the solvent gave a white foam, which was purified
by flash chromatography in silica (eluent: toluene/triethylamine,
100:1) to produce the corresponding ligand as a white solid.
L1: Yield: 115 mg (33%). 31P NMR (161.9 MHz, C6D6), δ: 131.4
(s). 1H NMR (400 MHz, C6D6), δ: 1.37 (s, 9H, CH3,
tBu), 1.43 (s,
9H, CH3,
tBu), 1.67 (s, 3H, CH3), 1.74 (s, 3H, CH3), 1.94 (s, 3H,
SCH3), 2.02 (s, 3H, CH3), 2.08 (s, 3H, CH3), 6.96−7.06 (m, 3H,
CH=), 7.07−7.12 (m, 3H, CH=), 7.16−7.18 (m, 1H, CH=), 7.27−
7.36 (m, 2H, CH=), 7.49−7.51 (m, 1H, CH=), 7.58−7.69 (m, 4H,
CH=). 13C NMR (100.6 MHz, C6D6), δ: 15.5 (SCH3), 16.4 (CH3),
16.6 (CH3), 20.2 (CH3), 20.3 (CH3), 31.3 (d, CH3,
tBu, JC‑P = 5.1
Hz), 31.7 (CH3,
tBu), 34.7 (C, tBu), 34.7 (C, tBu), 122.2−148.0
(aromatic carbons). Anal. Calcd (%) for C45H47O3PS: C 77.33, H
6.78, S 4.59. Found: C 77.07, H 6.76, S 4.57. MS HR-ESI [found
721.2871, C45H47O3PSNa (M + Na)
+ requires 721.2876].
L2: Yield: 157 mg (45%). 31P NMR (161.9 MHz, C6D6), δ: 132.1
(s). 1H NMR (400 MHz, C6D6), δ: 1.22 (s, 9H, CH3,
tBu), 1.46 (s,
9H, CH3,
tBu), 1.69 (s, 3H, CH3), 1.87 (s, 3H, CH3), 1.96 (s, 3H,
CH3), 2.06 (s, 3H, SCH3), 2.19 (s, 3H, CH3), 6.97−7.07 (m, 4H,
CH=) 7.11−7.17 (m, 3H, CH=), 7.19−7.31 (m, 4H, CH=), 7.58−
7.60 (m, 2H, CH=), 7.70−7.72 (m, 1H, CH=). 13C NMR (100.6
MHz, C6D6), δ: 16.2 (CH3), 16.3 (CH3), 16.5 (CH3), 16.6 (CH3),
20.1 (SCH3), 31.3 (d, CH3,
tBu, JC‑P = 5.1 Hz), 31.5 (CH3,
tBu), 34.5
(C, tBu), 34.7 (C, tBu), 122.7−147.4 (aromatic carbons). Anal. Calcd
(%) for C45H47O3PS: C 77.33, H 6.78, S 4.59. Found: C 77.14, H
6.76, S 4.58. MS HR-ESI [found 721.2871, C45H47O3PSNa (M +
Na)+ requires 721.2876].
L3: Yield: 150 mg (41%). 31P NMR (161.9 MHz, C6D6), δ: 131.7
(s). 1H NMR (400 MHz, C6D6), δ: 0.93 (d, 3H, CH3, S
iPr, 3JH‑H =
6.6 Hz), 1.03 (d, 3H, CH3, S
iPr, 3JH‑H = 6.6 Hz), 1.25 (s, 9H, CH3,
tBu), 1.47 (s, 9H, CH3,
tBu), 1.67 (s, 3H, CH3), 1.71 (s, 3H, CH3),
2.03 (s, 3H, CH3), 2.05 (s, 3H, CH3), 3.20 (m, 1H, CH, S
iPr), 6.93−
6.98 (m 2H, CH=), 7.00−7.14 (m, 4H, CH=), 7.18−7.24 (m, 3H,
CH=), 7.44−7.46 (m, 1H, CH=), 7.55−7.60 (d, 1H, CH=, 3JH‑H =
8.8 Hz), 7.65−7.70 (m, 3H, CH=). 13C NMR (100.6 MHz, C6D6), δ:





tBu), 34.5 (2x C, tBu),
36.0 (CH, SiPr), 122.6−147.9 (aromatic carbons). Anal. Calcd (%)
for C47H51O3PS: C 77.65, H 7.07, S 4.41. Found: C 77.5314, H 7.05,
S 4.39. MS HR-ESI [found 749.3186, C47H51O3PSNa (M + Na)
+
requires 749.3189].
L5: Yield: 179 mg (47%). 31P NMR (161.9 MHz, C6D6), δ: 131.7
(s). 1H NMR (400 MHz, C6D6), δ: 0.85−1.04 (m, 5H, CH2, SCy),
1.12−1.16 (m, 1H, CH2, SCy), 1.22 (s, 9H, CH3, tBu), 1.24−1.28 (m,
1H, CH2, SCy), 1.34−1.39 (m, 2H, CH2, SCy), 1.42 (s, 9H, CH3,
tBu), 1.62 (s, 3H, CH3), 1.66 (s, 3H, CH3), 1.86−1.90 (m, 1H, CH2,
SCy), 1.98 (s, 3H, CH3), 2.00 (s, 3H, CH3), 2.97−3.02 (m, 1H, CH,
SCy), 6.89−6.93 (m, 2H, CH=), 6.95−6.97 (m, 2H, CH=), 7.06−
7.08 (m, 2H, CH=), 7.14−7.15 (m, 2H, CH=), 7.49−7.56 (m, 3H,
CH=), 7.61−7.65 (m, 3H, CH=). 13C NMR (100.6 MHz, C6D6), δ:
16.3 (CH3), 16.5 (CH3), 20.0 (CH3), 20.2 (CH3), 25.6 (CH2, SCy),
25.8 (CH2, SCy), 25.9 (CH2, SCy), 31.4 (CH3,
tBu), 31.4 (CH3,
tBu), 32.9 (CH2, SCy), 33.2 (CH2, SCy), 34.6 (C,
tBu), 34.6 (C, tBu),
44.8 (CH, SCy), 122.4−147.9 (aromatic carbons). Anal. Calcd (%)
for C50H55O3PS: C 78.30, H 7.23, S 4.18. Found: C 78.16, H 7.21, S
4.15. MS HR-ESI [found 789.3500, C50H55O3PSNa (M + Na)
+
requires 789.3502].
L6: Yield: 129.1 mg (34%). 31P NMR (161.9 MHz, C6D6), δ: 136.5
(s). 1H NMR (400 MHz, C6D6), δ: 1.26 (s, 9H, CH3,
tBu), 1.28 (s,
18H, CH3,
tBu), 1.44 (s, 9H, CH3,
tBu), 1.93 (s, 3H, SCH3), 6.95−
7.05 (m, 3H, CH=), 7.08−7.14 (m, 2H, CH=), 7.17−7.21 (m, 1H,
CH=), 7.28−7.36 (m, 4H, CH=), 7.51−7.63 (m, 4H, CH=), 7.70−
7.75 (m, 2H, CH=). 13C NMR (100.6 MHz, C6D6), δ: 15.3 (SCH3),
31.0 (d, CH3,
tBu, JC‑P = 1.8 Hz), 31.1 (d, CH3,
tBu, JC‑P = 3.0 Hz),
31.4 (d, CH3, 2x
tBu, JC‑P = 3.0 Hz), 34.3 (C,
tBu), 34.4 (C, tBu), 35.3
(C, tBu), 35.4 (C, tBu), 122.9−147.9 (aromatic carbons). Anal. Calcd
(%) for C49H55O3PS: C 77.95, H 7.34, S 4.25. Found: C 77.87, H
7.32, S 4.24. MS HR-ESI [found 777.3528, C49H55O3PSNa (M +
Na)+ requires 777.3502].
L7: Yield: 251 mg (64%). 31P NMR (161.9 MHz, C6D6), δ: 131.7
(s). 1H NMR (400 MHz, C6D6), δ: 0.94 (d, 3H, CH3, S
iPr, 3JH‑H =
6.6 Hz), 1.00 (d, 3H, CH3, S
iPr, 3JH‑H = 6.6 Hz), 1.25 (s, 9H, CH3,
tBu), 1.27 (s, 9H, CH3,
tBu), 1.31 (s, 9H, CH3,
tBu), 1.46 (s, 9H,
CH3,
tBu), 3.18−3.25 (m, 1H, CH, SiPr), 6.95−7.03 (m, 2H, CH=),
7.08−7.14 (m, 1H, CH=), 7.18−7.22 (m, 1H, CH=), 7.25−7.30 (m,
2H, CH=), 7.34−7.36 (m, 2H, CH=), 7.52−7.62 (m, 6H, CH=),
7.69−7.72 (m, 2H, CH=). 13C NMR (100.6 MHz, C6D6), δ: 22.4
(CH3, S
iPr), 23.0 (CH3, S
iPr), 31.0 (d, CH3,
tBu, JC‑P = 1.9 Hz), 31.2
(d, CH3,
tBu, JC‑P = 3.0 Hz), 31.2 (d, CH3, 2x
tBu, JC‑P = 2.2 Hz CH3,
tBu), 34.3 (C, tBu), 34.4 (C, tBu), 35.2 (C, tBu), 35.3 (C, tBu), 36.0
(CH, SiPr), 122.6−147.7 (aromatic carbons). Anal. Calcd (%) for
C51H59O3PS: C 78.23, H 7.59, S 4.09. Found: C 78.01, H 7.55, S 4.06.
MS HR-ESI [found 805.3813, C51H59O3PSNa (M + Na)
+ requires
805.3815].
L8: Yield: 55 mg (11%). 31P NMR (161.9 MHz, C6D6), δ: 135.4
(s). 1H NMR (400 MHz, C6D6), δ: 1.23 (s, 18H, CH3,
tBu), 1.25 (s,
9H, CH3,
tBu), 1.31 (s, 9H, CH3,
tBu), 6.79−6.82 (m, 2H, CH=),
6.92−6.99 (m, 2H, CH=), 7.04−7.12 (m, 2H, CH=), 7.14−7.17 (m,
1H, CH=), 7.28−7.36 (m, 6H, CH=), 7.40−7.42 (m, 1H, CH=, 3JH‑H
= 8.7 Hz), 7.48−7.59 (m, 7H, CH=).13C NMR (100.6 MHz, C6D6),
δ: 30.9 (2x CH3,
tBu), 31.2 (2x CH3,
tBu), 34.3 (C, tBu), 34.3 (C,
tBu), 35.2 (2x C, tBu), 122.5−146.8 (aromatic carbons). Anal. Calcd
(%) for C54H57O3PS: C 79.38, H 7.03, S 3.92. Found: C 79.15, H
6.99, S 3.90. MS HR-ESI [found 839.3655, C54H57O3PSNa (M +
Na)+ requires 839.3658].
L9: Yield: 213 mg (52%). 31P NMR (161.9 MHz, C6D6), δ: 135.6
(s). 1H NMR (400 MHz, C6D6), δ: 0.84−1.07 (m, 5H, CH2, SCy),
1.26 (s, 9H, CH3,
tBu), 1.27 (s, 9H, CH3,
tBu), 1.32 (s, 9H, CH3,
tBu), 1.37−1.43 (m, 3H, CH2, SCy), 1.47 (s, 9H, CH3, tBu), 1.69−
1.72 (b, 1H, CH2, SCy), 1.87−1.90 (b, 1H, CH2, SCy), 3.02−3.07
(m, 1H, CH, SCy), 6.95−7.05 (m, 4H, CH=), 7.09−7.14 (m, 2H,
CH=), 7.19−7.22 (m, 1H, CH=), 7.24−7.29 (m, 1H, CH=), 7.34−
7.36 (m, 2H, CH=), 7.53−7.54 (m, 1H, CH=), 7.57−7.63 (m, 4H,
CH=), 7.68−7.71 (m, 1H, CH=). 13C NMR (100.6 MHz, C6D6), δ:
25.6 (CH2, SCy), 25.8 (CH2, SCy), 25.9 (CH2, SCy), 31.0 (d, CH3,
tBu, JC‑P = 1.6 Hz), 31.2 (CH3,
tBu), 31.3 (d, CH3, 2x
tBu, JC‑P = 1.6
Hz), 32.8 (CH2, SCy), 33.3 (CH2, SCy), 34.3 (C,
tBu), 34.4 (C, tBu),
35.2 (C, tBu), 35.3 (C, tBu), 44.8 (CH, SCy), 122.6−147.7 (aromatic
carbons). Anal. Calcd (%) for C54H63O3PS: C 78.80, H 7.71, S 3.89.
Found: C 78.62, H 7.69, S 3.87. MS HR-ESI [found 845.4124,
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General Procedure for the Preparation of Iridium Catalyst
Precursors [Ir(cod)(L1−L9)BArF]. The Ir catalyst precursors were
prepared following a methodology previously developed in our
group.33 The corresponding ligand (0.037 mmol) was dissolved in
CH2Cl2 (2.5 mL), and [Ir(μ-Cl)(cod)]2 (12.5 mg, 0.0185 mmol) was
added. The reaction was refluxed at 50 °C for 1 h. After 5 min at
room temperature, NaBArF (38.6 mg, 0.041 mmol) and water (2.5
mL) were added and the reaction was stirred vigorously for 30 min at
room temperature. The phases were separated, and the aqueous one
was extracted twice with CH2Cl2. The combined organic phases were
dried with MgSO4, and the resulting crude was purified by flash
chromatography on silica (CH2Cl2/hexane, 1:1) to give orange-red
air-stable solids.
[Ir(cod)(L1)]BArF. Yield: 65 mg (93%).
31P NMR (161.9 MHz,
CDCl3), δ: 108.5 (s).
1H NMR (400 MHz, CDCl3), δ: 1.34 (s, 9H,
CH3,
tBu), 1.59 (s, 3H, CH3), 1.62 (s, 9H, CH3,
tBu), 1.67 (s, 3H,
CH3), 1.81−1.95 (b, 2H, CH2, cod), 1.95−2.03 (b, 6H, CH2, cod),
2.18 (s, 3H, CH3), 2.24 (s, 3H, CH3), 2.55 (s, 3H, CH3, SMe), 3.27
(b, 1H, CH=, cod), 4.50 (b, 1H, CH=, cod), 4.72−4.73 (b, 1H, CH=,
cod), 4.92−4.93 (b, 1H, CH=, cod), 6.83−6.85 (m, 1H, CH=), 7.21
(m, 1H, CH=), 7.32−7.42 (m, 2H, CH=), 7.51 (m, 4H, CH=), 7.55−
7.61 (m, 3H, CH=), 7.70 (m, 10H, CH=), 7.90 (d, 1H, CH=, 3JH‑H =
9.0 Hz), 7.97 (d, 1H, CH=, 3JH‑H = 8.6 Hz), 8.01 (d, 1H, CH=), 8.15
(m, 2H, C=). 13C NMR (100.6 MHz, CDCl3), δ: 16.2 (CH3), 16.2
(CH3), 20.1 (CH3), 20.3 (CH3), 20.7 (CH3, SMe), 30.0 (CH2, cod),
30.9 (CH2, cod), 31.1 (CH2, cod), 32.1 (CH3,
tBu), 32.7 (CH3,
tBu),
33.8 (CH2, cod), 34.8 (C,
tBu), 35.6 (C, tBu), 69.9 (CH=, cod), 72.6
(CH=, cod), 98.0 (d, CH=, cod, JC‑P = 15.3 Hz), 100.2 (d, CH=, cod,
JC‑P = 15.3 Hz), 117.4−146.7 (aromatic carbons), 161.7 (q, C-B,
BArF,
1JC‑B = 49.7 Hz). Anal. Calcd (%) for C85H71BF4IrO3PS: C
54.81, H 3.84, S 1.72. Found: C 54.75, H 3.84, S 1.72. MS HR-ESI
[found 999.3542, C53H59IrO3PS (M)
+ requires 999.3546].
[Ir(cod)(L2)]BArF. Yield: 62 mg (89%).
31P NMR (161.9 MHz,
CDCl3), δ: 95.3 (s).
1H NMR (400 MHz, CDCl3), δ: 0.69 (s, 9H,
CH3,
tBu), 1.48 (s, 9H, CH3,
tBu), 1.69 (m, 2H, CH2, cod), 1.82 (s,
3H, CH3), 1.84 (s, 3H, CH3), 2.00 (b, 3H, CH2, cod), 2.08−2.13 (b,
2H, CH2, cod), 2.24 (s, 3H, CH3), 2.31 (s, 3H, CH3), 2.33−2.38 (b,
1H, CH2, cod), 2.69 (s, 3H, CH3, SMe), 2.97 (b, 1H, CH=, cod),
4.51 (b, 1H, CH=, cod), 5.32 (b, 2H, CH=, cod), 7.01−7.09 (m, 3H,
C=), 7.17 (d, 1H, CH=, 3JH‑H = 9.1 Hz), 7.27 (b, 1H, CH=), 7.34−
7.37 (m, 2H, CH=), 7.52 (m, 5H, CH=), 7.61−7.65 (m, 1H, CH=),
7.71 (m, 8H, CH=), 7.77 (d, 1H, CH=, 3JH‑H = 8.8 Hz), 7.89 (d, 1H,
CH=, 3JH‑H = 9.0 Hz), 7.94 (d, 1H, CH=,
3JH‑H = 8.1 Hz), 8.00 (d,
1H, CH=, 3JH‑H = 8.1 Hz), 8.14 (d, 1H, CH,
3JH‑H = 8.8 Hz).
13C
NMR (100.6 MHz, CDCl3), δ: 16.3 (CH3), 16.6 (CH3), 16.8 (CH3,
SMe), 20.3 (CH3), 20.5 (CH3), 28.7 (CH2, cod), 30.2 (CH2, cod),
31.0 (CH3,
tBu), 31.9 (CH2, cod), 32.5 (CH3,
tBu), 32.7 (CH2, cod),
34.4 (C, tBu), 35.1 (C, tBu), 69.9 (CH=, cod), 78.6 (CH=, cod), 97.1
(d, CH=, cod, JC‑P = 18.3 Hz), 98.5 (d, CH=, cod, JC‑P = 14.5 Hz),
117.4−147.3 (aromatic carbons), 161.7 (q, C-B, BArF, 1JC‑B = 49.7
Hz). Anal. Calcd (%) for C85H71BF4IrO3PS: C 54.81, H 3.84, S 1.72.
Found: C 54.63, H 3.82, S 1.71. MS HR-ESI [found 999.3544,
C53H59IrO3PS (M)
+ requires 999.3546].
[Ir(cod)(L3)]BArF. Yield: 64 mg (91%).
31P NMR (161.9 MHz,
CDCl3), δ: 92.1 (s).
1H NMR (400 MHz, CDCl3), δ: 0.67 (s, 9H,
CH3,
tBu), 0.99−1.01 (m, 6H, CH2, SiPr), 1.51 (s, 9H, CH3, tBu),
1.72−1.77 (m, 2H, CH2, cod), 1.84 (s, 3H, CH3), 1.85 (s, 3H, CH3),
2.03−2.13 (b, 3H, CH2, cod), 2.24 (s, 3H, CH3), 2.32 (s, 3H, CH3),
2.39−2.47 (b, 3H, CH2, cod), 3.10 (b, 1H, CH=, cod), 3.90−3.97 (m,
1H, CH, iPr), 4.34 (b, 1H, CH=, cod), 5.56 (b, 2H, CH=, cod),
7.03−7.07 (m, 3H, CH=), 7.11 (d, 1H, CH=, 3JH‑H = 9.1 Hz) 7.29 (s,
1H, CH=), 7.34−7.36 (m, 2H, CH=), 7.49−7.52 (m, 5H, CH=), 7.64
(t, 1H, CH=, 3JH‑H = 7.4 Hz), 7.72 (m, 8H, CH=), 7.78 (d, 1H, CH=,
3JH‑H = 8.7 Hz), 7.87 (d, 1H, CH=,
3JH‑H = 9.0 Hz), 7.93 (d, 1H, C=,
3JH‑H = 8.2 Hz), 8.00 (d, 1H, CH=,
3JH‑H = 8.1 Hz), 8.12 (d, 1H,
CH=, 3JH‑H = 8.7 Hz).
13C NMR (100.6 MHz, CDCl3), δ: 16.3
(CH3), 16.6 (CH3), 20.3 (CH3), 20.5 (CH3), 22.5 (CH3, S
iPr), 22.7
(CH3, S
iPr), 29.2 (CH2, cod), 29.9 (CH2, cod), 31.0 (CH3,
tBu), 31.6
(CH2, cod), 32.8 (CH3,
tBu), 33.0 (CH2, cod), 34.4 (C,
tBu), 35.2
(C, tBu), 37.7 (CH, SiPr), 69.1 (CH=, cod), 75.9 (CH=, cod), 97.9
(d, CH=, cod, JC‑P = 17.7 Hz), 98.8 (d, CH=, cod, JC‑P = 14.3 Hz),
117.4−147.6 (aromatic carbons), 161.7 (q, C-B, BArF, 1JC‑B = 50.0
Hz). Anal. Calcd (%) for C87H75BF4IrO3PS: C 55.27, H 4.00, S 1.70.
Found: C 55.11, H 3.98, S 1.69. MS HR-ESI [found 1027.3854,
C55H63IrO3PS (M)
+ requires 1027.3859].
[Ir(cod)(L5)]BArF. Yield: 63 mg (88%).
31P NMR (161.9 MHz,
CDCl3), δ: 91.9 (s).
1H NMR (400 MHz, CDCl3), δ: 0.67 (s, 9H,
CH3,
tBu), 0.73 (m, 1H, CH2, SCy), 0.87−0.90 (m, 4H, CH2, SCy),
1.26 (m, 5H, SCy), 1.50 (s, 9H, CH3,
tBu), 1.64−1.68 (m, 1H, CH2,
cod), 1.84 (s, 3H, CH3), 1.85 (s, 3H, CH3),1.98−2.12 (b, 4H, CH2,
cod), 2.24 (s, 3H, CH3), 2.32 (s, 3H, CH3), 2.40−2.47 (m, 3H, CH2,
cod), 3.10 (b, 1H, CH=, cod), 3.73 (b, 1H, CH, SCy), 4.30−4.32 (b,
1H, CH=, cod), 5.58 (b, 2H, CH=, cod), 7.05−7.06 (m, 3H, CH=),
7.11 (d, 1H, CH=, 3JH‑H = 9.1 Hz), 7.28 (m, 1H, CH=), 7.31−37 (m,
2H, CH=), 7.47−7.52 (m, 5H, CH=), 7.62 (t, 1H, CH=, 3JH‑H = 7.4
Hz), 7.73 (m, 8H, CH=), 7.78 (d, 1H, CH=, 3JH‑H = 8.8 Hz), 7.86 (d,
1H, CH=, 3JH‑H = 9.1 Hz), 7.92 (d, 1H, C=,
3JH‑H = 8.3 Hz), 7.99 (d,
1H, CH=, 3JH‑H = 8.1 Hz), 8.10 (d, 1H, CH=,
3JH‑H = 8.7 Hz).
13C
NMR (100.6 MHz, CDCl3), δ: 16.3 (CH3), 16.6 (CH3), 20.3 (CH3),
20.5 (CH3), 22.7 (CH2, SCy), 24.6 (CH2, SCy), 25.0 (CH2, SCy),
25.5 (CH2, SCy), 29.1 (CH2, cod), 29.9 (CH2, cod), 31.0 (CH3,
tBu),
31.7 (CH2, cod), 32.0 (CH2, cod), 32.8 (CH3,
tBu), 34.4 (C, tBu),
35.2 (C, tBu), 46.0 (CH, SCy), 68.8 (CH=, cod), 75.6 (CH=, cod),
98.0 (d, CH=, cod, JC‑P = 17.8 Hz), 98.8 (d, CH=, cod, JC‑P = 14.7
Hz), 117.4−147.8 (aromatic carbons), 161.7 (q, C-B, BArF, 1JC‑B =
49.9 Hz). Anal. Calcd (%) for C90H79BF4IrO3PS: C 55.99, H 4.12, S
1.66. Found: C 55.73, H 4.10, S 1.65. MS HR-ESI [found 1067.4167,
C58H67IrO3PS (M)
+ requires 1067.4172].
[Ir(cod)(L6)BArF]. Yield: 64 mg (90%).
31P NMR (161.9 MHz,
CDCl3), δ: 98.7 (s).
1H NMR (400 MHz, CDCl3), δ: 0.74 (s, 9H,
CH3,
tBu), 1.31 (s, 9H, CH3,
tBu), 1.37 (s, 9H, CH3,
tBu), 1.54 (s,
9H, CH3,
tBu), 1.74−1.79 (b, 2H, CH2, cod), 2.10−2.25 (b, 5H,
CH2, cod), 2.36−2.38 (b, 1H, CH2, cod), 2.71 (s, 3H, SMe), 3.43 (b,
1H, CH=, cod), 4.60 (b, 1H, CH=, cod), 5.33 (b, 1H, CH=, cod),
5.40 (b, 1H, CH=, cod), 7.04−7.11 (m, 2H, C=), 7.16 (m, 1H,
CH=), 7.23 (m, 1H, CH=),7.29 (s, 1H, CH=), 7.31−7.32 (m, 1H,
CH=), 7.35−7.39 (m, 2H, CH=), 7.52 (b, 5H, CH=), 7.58−7.59 (m,
1H, CH=), 7.62−7.66 (m, 1H, CH=), 7.71 (m, 8H, CH=), 7.78 (d,
1H, CH=, 3JH‑H = 8.8 Hz), 7.89 (d, 1H, CH=,
3JH‑H = 9.0 Hz), 7.94
(d, 1H, CH=, 3JH‑H = 8.1 Hz), 8.01 (d, 1H, CH=,
3JH‑H = 8.2 Hz),
8.15 (d, 1H, CH=, 3JH‑H = 8.7 Hz).
13C NMR (100.6 MHz, CDCl3),
δ: 16.9 (CH3, SMe), 28.6 (CH2, cod), 29.7 (CH2, cod), 30.8 (CH3,
tBu), 31.3 (CH3,
tBu), 31.4 (CH3,
tBu), 31.5 (CH2, cod), 32.5 (CH3,
tBu), 32.9 (CH2, cod), 34.8 (C,
tBu), 34.9 (C, tBu), 35.0 (C, tBu),
35.9 (C, tBu), 69.8 (CH=, cod), 78.8 (CH=, cod), 97.4 (d, CH=, cod,
JC‑P = 17.5 Hz), 98.8 (d, CH=, cod, JC‑P = 14.8 Hz), 117.4−149.3
(aromatic carbons), 161.7 (q, C-B, BArF,
1JC‑B = 49.4 Hz). Anal.
Calcd (%) for C89H79BF4IrO3PS: C 55.72, H 4.15, S 1.67. Found: C
55.60, H 4.14, S 1.67. MS HR-ESI [found 1055.4170, C57H67IrO3PS
(M)+ requires 1055.4172].
[Ir(cod)(L7)]BArF. Yield: 67 mg (93%).
31P NMR (161.9 MHz,
CDCl3), δ: 95.6 (s).
1H NMR (400 MHz, CDCl3), δ: 0.74 (s, 9H,
CH3,
tBu), 1.03−1.05 (m, 6H, CH3, SiPr), 1.32 (s, 9H, CH3, tBu),
1.39 (s, 9H, CH3,
tBu), 1.56 (s, 9H, CH3,
tBu), 1.78−1.90 (b, 4H,
CH2, cod), 2.08−2.11 (m, 2H, CH2, cod), 2.39−2.51 (m, 2H, CH2,
cod), 3.56 (b, 1H, CH=, cod), 3.94−3.97 (m, 1H, CH, iPr), 4.41−
4.44 (b, 1H, CH=, cod), 5.57 (b, 1H, CH=, cod), 5.64 (b, 1H, CH=,
cod), 7.05 (d, 1H, CH=, 3JH‑H = 8.5 Hz), 7.09 (d, 1H, CH=,
3JH‑H =
8.5 Hz), 7.19−7.27 (m, 3H, CH=), 7.33−7.38 (m, 4H, CH=), 7.53
(m, 4H, CH=), 7.60 (s, 1H, CH=), 7.63−7.67 (m, 1H, CH=), 7.72
(m, 8H, CH=), 7.80 (d, 1H, CH=, 3JH‑H = 8.7 Hz), 7.87 (d, 1H, CH=,
3JH‑H = 9.1 Hz), 7.93 (d, 1H, C=,
3JH‑H = 8.3 Hz), 8.01 (d, 1H, CH=,
3JH‑H = 8.1 Hz), 8.13 (d, 1H, CH=,
3JH‑H = 8.7 Hz).
13C NMR (100.6
MHz, CDCl3), δ: 21.4 (CH3, S
iPr), 22.4 (CH3, S
iPr), 29.4 (CH2,
cod), 29.7 (CH2, cod), 30.8 (CH3,
tBu), 31.3 (CH3,
tBu), 31.4 (CH3,
tBu), 31.4 (CH2, cod), 31.5 (CH2, cod), 32.6 (CH3,
tBu), 34.8 (C,
tBu), 34.9 (C, tBu), 35.1 (C, tBu), 35.9 (C, tBu), 37.7 (CH, SiPr),
69.2 (CH=, cod), 75.9 (CH=, cod), 98.2 (d, CH=, cod, JC‑P = 19.8
Hz), 99.3 (d, CH=, cod, JC‑P = 13.7 Hz), 115.4−149.3 (aromatic
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carbons), 161.7 (q, C-B, BArF,
1JC‑B = 50.5 Hz). Anal. Calcd (%) for
C91H83BF4IrO3PS: C 56.15, H 4.30, S 1.65. Found: C 56.01, H 4.28, S
1.64. MS HR-ESI [found 1083.4482, C59H71IrO3PS (M)
+ requires
1083.4485].
[Ir(cod)(L8)]BArF. Yield: 64 mg (88%).
31P NMR (161.9 MHz,
CDCl3), δ: 96.5 (s).
1H NMR (400 MHz, CDCl3), δ: 0.68 (s, 9H,
CH3,
tBu), 1.31 (s, 9H, CH3,
tBu), 1.39 (s, 9H, CH3,
tBu), 1.70 (s,
9H, CH3,
tBu), 1.84−1.90 (b, 2H, CH2, cod), 1.97−2.07 (b, 2H,
CH2, cod), 2.24−2.33 (b, 2H, CH2, cod), 2.39−2.43 (b, 2H, CH2,
cod), 3.45 (b, 1H, CH=, cod), 4.44 (b, 1H, CH=, cod), 4.76 (b, 1H,
CH=, cod), 5.30 (b, 1H, CH=, cod), 7.14−7.21 (m, 6H, CH=),
7.32−7.48 (m, 9H, CH=), 7.51 (m, 4H, CH=), 7.63−7.64 (m, 1H,
CH=), 7.70−7.72 (m, 8H, CH=), 7.90 (d, 2H, CH=, 3JH‑H = 8.8 Hz),
8.07−8.11 (m, 2H, CH=), 8.25 (d, 1H, CH=, 3JH‑H = 8.9 Hz). 13C
NMR (100.6 MHz, CDCl3), δ: 28.2 (CH2, cod), 29.3 (CH2, cod),
30.8 (CH3,
tBu), 31.0 (CH2, cod), 31.3 (CH3,
tBu), 31.4 (CH3,
tBu),
31.6 (CH2, cod), 32.9 (CH3,
tBu), 34.8 (C, tBu), 34.9 (C, tBu), 35.0
(C, tBu), 36.0 (C, tBu), 69.1 (CH=, cod), 77.2 (CH=, cod), 100.8
(CH=, cod), 101.7 (CH=, cod), 117.4−149.5 (aromatic carbons),
161.7 (q, C-B, BArF,
1JC‑B = 50.0 Hz). Anal. Calcd (%) for
C94H81BF4IrO3PS: C 57.00, H 4.12, S 1.62. Found: C 56.88, H 4.10, S
1.62. MS HR-ESI [found 1117.4325, C62H69IrO3PS (M)
+ requires
1117.4329].
[Ir(cod)(L9)]BArF. Yield: 64 mg (87%).
31P NMR (161.9 MHz,
CDCl3), δ: 95.6 (s).
1H NMR (400 MHz, CDCl3), δ: 0.73 (s, 9H,
CH3,
tBu), 0.79 (b, 1H, CH2, SCy), 1.08 (m, 2H, CH2, SCy), 1.31 (s,
9H, CH3,
tBu), 1.34 (b, 3H, CH2, SCy), 1.38 (s, 9H, CH3,
tBu),
1.45−1.46 (m, 3H, CH2, SCy), 1.56 (s, 9H, CH3, tBu), 1.62−1.71 (b,
3H, CH2, cod and CH2, SCy), 1.86−1.89 (b, 2H, CH2, cod) 2.09−
2.11 (b, 2H, CH2, cod), 2.38−2.49 (b, 2H, CH2, cod), 3.54 (b, 1H,
CH=, cod), 3.74 (m, 1H, CH, SCy), 4.37−4.41 (b, 1H, CH=, cod),
5.62 (b, 2H, CH=, cod), 7.04−7.09 (m, 2H, CH=), 7.18−7.25 (m,
3H, CH=), 7.32−7.38 (m, 3H, CH=), 7.48−7.52 (m, 4H, CH=),
7.58−7.59 (m, 1H, CH=), 7.62−7.66 (m, 2H, CH=), 7.72 (m, 8H,
CH=), 7.80 (d, 1H, CH=, 3JH‑H = 8.8 Hz), 7.86 (d, 1H, CH=,
3JH‑H =
9.1 Hz), 7.92 (d, 1H, C=, 3JH‑H = 8.2 Hz), 8.00 (d, 1H, CH=,
3JH‑H =
8.3 Hz), 8.11 (d, 1H, CH=, 3JH‑H = 8.7 Hz).
13C NMR (100.6 MHz,
CDCl3), δ: 22.7 (CH2, SCy), 24.6 (CH2, SCy), 25.0 (CH2, SCy),





cod), 32.1 (CH2, cod), 32.6 (CH3,
tBu), 34.8 (C, tBu), 34.9 (C, tBu),
35.0 (C, tBu), 35.9 (C, tBu), 46.0 (CH, SCy), 68.9 (CH=, cod), 75.6
(CH=, cod), 98.3 (d, CH=, cod, JC‑P = 17.9 Hz), 99.2 (d, CH=, cod,
JC‑P = 14.2 Hz), 117.4−149.2 (aromatic carbons), 161.7 (q, C-B,
BArF,
1JC‑B = 49.9 Hz). Anal. Calcd (%) for C94H87BF4IrO3PS: C
56.83, H 4.41, S 1.61. Found: C 56.65, H 4.40, S 1.60. MS HR-ESI
[found 1123.4795, C62H75IrO3PS (M)
+ requires 1123.4798].
General Procedure for the Asymmetric Hydrogenation. The
alkene (0.25 mmol) and Ir complex (1 mol %) were dissolved in
CH2Cl2 (2 mL) and placed in a high-pressure autoclave. The
autoclave was purged four times with hydrogen. Then, it was
pressurized at the desired pressure. After the desired reaction time,
the autoclave was depressurized and the solvent evaporated off. The
residue was dissolved in Et2O (1.5 mL) and filtered through a short
plug of celite. The enantiomeric excess was determined by chiral GC
or chiral HPLC (see the Supporting Information for details), and
conversions were determined by 1H NMR.
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